安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- TYK2: an emerging therapeutic target in rheumatic disease
Tyrosine kinase 2 (TYK2), a Janus kinase family member, is involved in immune signalling and is implicated in autoimmune diseases such as systemic lupus erythematosus; inhibitors of TYK2 show
- TYK2 Immune Pathway Fact Sheet – Bristol Myers Squibb
Tyrosine kinase 2 (TYK2) is an intracellular enzyme that mediates immune signaling and inflammatory signaling pathways 1-7 TYK2 is important in both innate and adaptive immune cells and is an essential component of maintaining normal immune responses
- TYK2 Tyrosine Kinase 2 Pathway - Immunology Pathways
TYK2 is an intracellular kinase in the Janus kinase (JAK) family of enzymes TYK2 and JAK1 2 3 proteins work in pairs (dimers) to relay immune signals initiated by specific cytokines 1
- TYK2 Gene - GeneCards | TYK2 Protein | TYK2 Antibody
TYK2 (Tyrosine Kinase 2) is a Protein Coding gene Diseases associated with TYK2 include Immunodeficiency 35 and Primary Cutaneous Anaplastic Large Cell Lymphoma
- TYK2 tyrosine kinase 2 [Homo sapiens (human)] - Gene - NCBI
Gene target information for TYK2 - tyrosine kinase 2 (human) Find diseases associated with this biological target and compounds tested against it in bioassay experiments
- Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK . . .
TYK2 is a key mediator of IL12, IL23, and type I interferon signaling, and these cytokines have been implicated in the pathogenesis of multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, lupus, and inflammatory bowel diseases
- Unlocking TYK2 in Autoimmune and Inflammatory Diseases
It plays a key role in normal physiology and pathology, especially in immune-mediated inflammatory diseases TYK2 is widely expressed and is involved in the signaling of several key cytokines, such as type 1 interferon (IFN), interleukin (IL)-23, IL-12, IL-10 and IL-6
- What are the therapeutic candidates targeting TYK2?
There is significant potential for TYK2 inhibitors in conditions like psoriatic arthritis, rheumatoid arthritis, SLE, and even in combination regimens where synergistic improvements may address unmet clinical needs
|
|
|